Endozepine-like proteins, polynucleotides encoding them and methods of using the same
OwnerEsha A. Gangolli, David J. Stoneinventors
Life of this patent
Estimating the term…
Abstract
Disclosed are novel polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.
Claims41
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7, and 10;
- (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
- (c) an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10;
- and
- (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10 wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.
2 The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10.
The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, 4, 6, 8, and 9.
An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10;
- (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
- (c) an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10;
- (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
- (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NO:
- 2, 5, 7 and 10, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
- and
- (f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).
The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a NOVX-associated disorder, wherein said therapeutic is selected from the group consisting of a NOVX polypeptide, a NOVX nucleic acid, and a NOVX antibody.
A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NO:
- 2, 5, 7 and 10, or a biologically active fragment thereof.
Dependencies are inferred from the claim text.